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Patients with active acute or chronic infection were excluded from our study. 2 Potentially eligible participants were recruited only after confirming the absence of symptoms and signs suggestive of infection in the history and the physical examination. Likewise, patients with conditions that might be associated with systemic inflammatory markers, such as neoplasms or pregnancy, were excluded.
Dr Akboga et al 1 are correct that several surrogate markers of inflammation, easily obtainable through the blood count, have been described over the last decades. [3] [4] [5] [6] We did not include them in our primary analyses as their current level of scientific evidence to assess inflammation was limited in patients with systemic lupus erythematosus compared with the erythrocyte sedimentation rate, fibrinogen, and C-reactive protein. However, additional analyses following the correspondents' suggestion revealed that resting heart rate (RHR) was neither associated with white blood cell (
Finally, the median systemic lupus erythematous disease activity index in our whole cohort was 2.0 (interquartile range 0 to 4) and the percentage of patients taking nonsteroidal anti-inflammatory drug was 5%, corticosteroids 53.5%, and immunosuppressive medications 36.6%. These values across RHR quartiles are presented in Table 1 . Importantly, accounting for these variables in the analyses did not modify the final results.
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